Bajis S, et al. - Researchers examined people going to a homelessness service in Sydney to assess hepatitis C virus (HCV) RNA prevalence, liver disease burden, how well they are linked to care, and treatment uptake and outcomes. Among 202 participants, 39% reported ever injecting drugs, of whom 63% (n=49) did so in the previous month. Overall, HCV RNA was detected in 23% (n=47); cirrhosis was reported in 6%. Participants with either injecting or incarceration history had HCV RNA prevalence of 35% vs 4% in participants without these risk factors. Therapy was begun for 23 (49%) people of those with detectable HCV RNA; of these, 65% (n=15) achieved sustained virological response, while no available treatment outcome was noted for the rest. Virological failure was not documented in any of the participants. They noted encouraging HCV direct-acting antiviral (DAA) treatment uptake among these people, however, there is a necessity for pioneering models of HCV care to enhance their connection to care and treatment uptake.